Salivary MicroRNA in Pancreatic Cancer Patients.
Salivary MicroRNA in Pancreatic Cancer Patients.
复制标题
DOI：
10.1371/journal.pone.0130996
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Cordelier P
中科院分区：
文献类型：
--
作者：
Humeau M;Vignolle-Vidoni A;Sicard F;Martins F;Bournet B;Buscail L;Torrisani J;Cordelier P
胰腺癌是西方国家第四大癌症死亡原因，在常见癌症中一年生存率最低。胰腺癌诊断缺乏可靠的生物标志物，迫切需要用于根治性手术。由于 microRNA (miRNA) 最近成为这种疾病的候选生物标志物，我们在目前的试点研究中探索了不适合手术的胰腺肿瘤患者、癌前病变、炎症性疾病或无癌症患者之间唾液 microRNA 谱的差异，作为潜在的早期诊断工具。在内窥镜检查期间获得胰腺癌 (n = 7)、胰腺炎 (n = 4)、IPMN (n = 2) 或健康对照 (n = 4) 患者的全唾液样本。总 RNA 分离后，使用 Biomark Fluidgm 通过 q(RT)PCR 筛选 94 种候选 miRNA 的表达。将人源性胰腺癌细胞异种移植到无胸腺小鼠体内，作为胰腺癌的实验模型。我们发现，与对照组相比，胰腺癌患者唾液中的 hsa-miR-21、hsa-miR-23a、hsa-miR-23b 和 miR-29c 显着上调，敏感性分别为 71.4%、85.7%、85.7% 和 57%，特异性极佳 (100%)。有趣的是，hsa-miR-23a 和 hsa-miR23b 在胰腺癌前驱病变患者的唾液中过度表达。我们发现，与对照组相比，胰腺炎患者唾液中 hsa-miR-210 和 let-7c 过表达，敏感性分别为 100% 和 75%，特异性为 100% 和 80%。与诊断为胰腺炎的患者相比，最后的 hsa-miR-216 在癌症患者中表达上调，敏感性为 50%，特异性为 100%。在 PDAC 实验模型中，唾液 microRNA 检测先于癌细胞标记物的系统检测。我们的新发现表明，唾液 miRNA 对不适合手术的胰腺癌患者具有歧视性。此外，我们在实验模型中证明，唾液 miRNA 检测先于癌细胞标记物的系统检测。这项研究源于使用唾液 miRNA 作为生物标志物来早期诊断不可切除的胰腺癌患者。
Pancreatic cancer is the fourth leading cause of cancer death in Western countries, with the lowest 1-year survival rate among commonly diagnosed cancers. Reliable biomarkers for pancreatic cancer diagnosis are lacking and are urgently needed to allow for curative surgery. As microRNA (miRNA) recently emerged as candidate biomarkers for this disease, we explored in the present pilot study the differences in salivary microRNA profiles between patients with pancreatic tumors that are not eligible for surgery, precancerous lesions, inflammatory disease or cancer-free patients as a potential early diagnostic tool. Whole saliva samples from patients with pancreatic cancer (n = 7), pancreatitis (n = 4), IPMN (n = 2), or healthy controls (n = 4) were obtained during endoscopic examination. After total RNA isolation, expression of 94 candidate miRNAs was screened by q(RT)PCR using Biomark Fluidgm. Human-derived pancreatic cancer cells were xenografted in athymic mice as an experimental model of pancreatic cancer. We identified hsa-miR-21, hsa-miR-23a, hsa-miR-23b and miR-29c as being significantly upregulated in saliva of pancreatic cancer patients compared to control, showing sensitivities of 71.4%, 85.7%, 85,7% and 57%, respectively and excellent specificity (100%). Interestingly, hsa-miR-23a and hsa-miR23b are overexpressed in the saliva of patients with pancreatic cancer precursor lesions. We found that hsa-miR-210 and let-7c are overexpressed in the saliva of patients with pancreatitis as compared to the control group, with sensitivity of 100% and 75%, and specificity of 100% and 80%, respectively. Last hsa-miR-216 was upregulated in cancer patients as compared to patients diagnosed with pancreatitis, with sensitivity of 50% and specificity of 100%. In experimental models of PDAC, salivary microRNA detection precedes systemic detection of cancer cells markers. Our novel findings indicate that salivary miRNA are discriminatory in pancreatic cancer patients that are not eligible for surgery. In addition, we demonstrate in experimental models that salivary miRNA detection precedes systemic detection of cancer cells markers. This study stems for the use of salivary miRNA as biomarker for the early diagnosis of patients with unresectable pancreatic cancer.
登录
查看更多内容
影响因子：
3.6
作者：
Bournet, B.;Pointreau, A.;Buscail, L.
通讯作者：
Buscail, L.
影响因子：
11.5
作者：
Matse, Johannes H.;Yoshizawa, Janice;Wong, David T. W.
通讯作者：
Wong, David T. W.
对口腔癌检测的唾液生物标志物的研究综述。
影响因子：
10.6
作者：
Cheng YS;Rees T;Wright J
通讯作者：
Wright J
影响因子：
4.8
作者：
Lau, Chang;Kim, Yong;Wong, David T. W.
通讯作者：
Wong, David T. W.
DOI：
10.1002/hed.21713
发表时间：
2012-02-01
影响因子：
2.9
作者：
Liu, Chung-Ji;Lin, Shu-Chun;Chang, Kuo-Wei
通讯作者：
Chang, Kuo-Wei